Loading
companiesCompany
TAE Life Sciences
TAE Life Sciences is developing boron neutron capture therapy, in which a boron drug collects in cancer cells and a hospital-based neutron beam then triggers a tiny nuclear reaction inside those cells to destroy them while sparing nearby healthy tissue.
Overview
TAE Life Sciences develops an accelerator-based boron neutron capture therapy (BNCT) platform licensed from fusion company TAE Technologies. Alphabeam is a compact, tunable low-energy neutron source designed for installation inside a hospital radiotherapy department. In BNCT a boron carrier accumulates in tumour cells and neutron capture releases an alpha particle and lithium nucleus with a range of about one cell diameter, giving cell-level targeting. The company launched in March 2018 with a USD 40 million Series A led by ARTIS Ventures and an agreement to deliver its first system to Neuboron Medtech in China. In September 2025 it signed an MOU with the University of Wisconsin-Madison to become the first US Alphabeam site with trials in head and neck and brain cancers, and reported preclinical data showing its boron compounds plus checkpoint inhibitors outperform either alone. Device and drugs remain investigational.
Headquarters
Irvine, CA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Led by ARTIS Ventures; company launched as a majority-owned subsidiary of fusion company TAE Technologies | 2018 | $40M | taelifesciences.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Startup
Website
Founded
2018
Notes
top- Caller's hint of Santa Monica was not confirmed: the website footer gives 9750 Irvine Blvd, Irvine, CA, and the 2018 launch release was datelined Foothill Ranch, CA. The main website returned HTTP 403 to curl but loaded via WebFetch. Founded year taken as the 2018 public launch. Later rounds (if any) are unsourced and omitted.
Similar pages
- CompanyNeutron Therapeutics
Shares Boron neutron capture therapy, Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex), Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Glioma & glioblastoma.
- CompanyStella Pharma
Shares Boron neutron capture therapy, Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex), Glioma & glioblastoma, Head and neck squamous cell carcinoma.
- CompanyNeuboron Medtech
Shares Boron neutron capture therapy, Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex).
- CompanySumitomo Heavy Industries
Shares Boron neutron capture therapy, Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex).
- TrialTo Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies
Shares Boron neutron capture therapy, Head and neck squamous cell carcinoma.
- IdeactHPV-DNA-adapted de-escalation of chemoradiation
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Head and neck squamous cell carcinoma.
- TreatmentAmifostine
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Head and neck squamous cell carcinoma.
- TechnologyRadiodynamic therapy and radiosensitising nanoparticles
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Head and neck squamous cell carcinoma.